Oxbow Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-142,798
| Closed | -$7M | – | 256 |
|
|
2025
Q4 | $7M | Buy |
+142,798
| New | +$6.66M | 0.62% | 42 |
|
|
2025
Q1 | – | Sell |
-137,172
| Closed | -$4.64M | – | 214 |
|
|
2024
Q4 | $4.64M | Sell |
137,172
-3,563
| -3% | -$128K | 0.55% | 49 |
|
|
2024
Q3 | $5.75M | Buy |
140,735
+4,430
| +3% | +$181K | 0.57% | 42 |
|
|
2024
Q2 | $5.25M | Buy |
136,305
+5,737
| +4% | +$241K | 0.62% | 41 |
|
|
2024
Q1 | $5.6M | Buy |
130,568
+268
| +0.2% | +$11.1K | 0.77% | 40 |
|
|
2023
Q4 | $4.83M | Sell |
130,300
-2,076
| -2% | -$74.5K | 0.73% | 37 |
|
|
2023
Q3 | $4.8M | Buy |
+132,376
| New | +$4.7M | 0.76% | 34 |
|
|
2019
Q2 | – | Sell |
-7,215
| Closed | -$377K | – | 309 |
|
|
2019
Q1 | $377K | Hold |
7,215
| – | – | 0.05% | 218 |
|
|
2018
Q4 | $345K | Sell |
7,215
-1,480
| -17% | -$72.9K | 0.05% | 211 |
|
|
2018
Q3 | $437K | Hold |
8,695
| – | – | 0.05% | 208 |
|
|
2018
Q2 | $438K | Hold |
8,695
| – | – | 0.06% | 205 |
|
|
2018
Q1 | $425K | Hold |
8,695
| – | – | 0.09% | 164 |
|
|
2017
Q4 | $386K | Hold |
8,695
| – | – | 0.07% | 184 |
|
|
2017
Q3 | $441K | Hold |
8,695
| – | – | 0.08% | 167 |
|
|
2017
Q2 | $469K | Hold |
8,695
| – | – | 0.08% | 171 |
|
|
2017
Q1 | $458K | Hold |
8,695
| – | – | 0.07% | 177 |
|
|
2016
Q4 | $418K | Hold |
8,695
| – | – | 0.05% | 194 |
|
|
2016
Q3 | $469K | Hold |
8,695
| – | – | 0.06% | 174 |
|
|
2016
Q2 | $471K | Hold |
8,695
| – | – | 0.07% | 175 |
|
|
2016
Q1 | $441K | Sell |
8,695
-141
| -2% | -$7.02K | 0.06% | 179 |
|
|
2015
Q4 | $445K | Sell |
8,836
-176
| -2% | -$8.97K | 0.06% | 184 |
|
|
2015
Q3 | $433K | Sell |
9,012
-22,504
| -71% | -$1.17M | 0.07% | 175 |
|
|
2015
Q2 | $1.64M | Sell |
31,516
-55
| -0.2% | -$3.1K | 0.21% | 115 |
|
|
2015
Q1 | $1.82M | Sell |
31,571
-1,920
| -6% | -$110K | 0.27% | 87 |
|
|
2014
Q4 | $1.79M | Buy |
33,491
+5,864
| +21% | +$328K | 0.25% | 92 |
|
|
2014
Q3 | $1.59M | Buy |
27,627
+3,776
| +16% | +$231K | 0.22% | 96 |
|
|
2014
Q2 | $1.59M | Buy |
23,851
+808
| +4% | +$54.7K | 0.21% | 97 |
|
|
2014
Q1 | $1.54M | Sell |
23,043
-2,008
| -8% | -$136K | 0.23% | 93 |
|
|
2013
Q4 | $1.67M | Buy |
25,051
+6,052
| +32% | +$392K | 0.24% | 94 |
|
|
2013
Q3 | $1.19M | Buy |
18,999
+1,192
| +7% | +$76.7K | 0.19% | 97 |
|
|
2013
Q2 | $1.11M | Buy |
+17,807
| New | +$1.13M | 0.19% | 88 |
|
Other funds holding GSK
JEST
Oxbow Advisors's GSK Position: Q1 2026 in Review
Oxbow Advisors sold out of GSK (GSK) in Q1 2026, closing a stake of 142,798 shares — an estimated $7M sold.
Oxbow Advisors first reported a position in GSK in Q2 2013 and held it in 31 quarters. The position peaked at $7M in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Oxbow Advisors reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
- Oxbow Advisors sold 142,798 GSK shares in Q1 2026, an estimated $7M.
- Oxbow Advisors first reported a position in GSK in Q2 2013 and held it in 31 quarters.
- Oxbow Advisors's GSK position peaked at $7M in Q4 2025.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Oxbow Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.